JPMorgan analyst Lisa Gill assumed coverage of GoodRx with a Neutral rating and price target of $7, up from $6. The analyst believes there is “growing positivity” around the structural set up as the company fully anniversaries the Kroger disruptions and pilots Express Scripts/Caremark partnerships. However, it wants to see traction around the expected inflection to the upside for GoodRx.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GDRX: